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Abstract 
Objectives: The pharmacological effects 
of Methylprednisolone and Cerebrolysin 
have been extensively debated, but from 
our knowledge there are no studies to 
evaluate the association of these two drugs 
in spinal cord injury (SCI). 
Methods: Twenty-four Wistar rats 
underwent traumatic spinal cord injury by 
using clip-compression model. The animals 
were divided into four groups: group I 
received Methylprednisolone (MP); group 
II was injected with Cerebrolysin (C); 
group III received Methylprednisolone 
together with Cerebrolysin (MP+C); in 
the control group we have performed only 
decompression. The motor recovery of the 
animals was evaluated using the Ferguson 
et al. modification of the BBB scale. After 
ten days the rats were sacrificed.  
Results: The study demonstrated that 
the MP + C group presented the most 
notable recovery of the motor function, but 
no statistically significant (p>0,05). The 
first and the second group also presented 
better results than the fourth group, but the 
enhanced recovery of those group relative 
to control group was not statistically 
significant (p>0,05)  
Conclusion: The combination of MP 
and Cerebrolysin in experimental 
conditions seems to have promising results, 
but more experimental and clinical studies 
are necessary to evaluate the real benefit for 
SCI patients. 
Keywords: Cerebrolysin, Methyl-
prednisolone, motor recovery, spinal cord 
injury. 
Introduction 
Spinal cord injury (SCI) is a devastating 
disease with a high morbi-mortality even in 
specialized centers.  The personal, familial 
and social implications of an injured patient 
are hardly quantifiable. There is a lack of 
evidence regarding this pathology in 
Romania, but according to literature data 
the incidence fluctuates between 10.4 and 
 
 
 
Romanian Neurosurgery (2011) XVIII 4: 390 - 399          391 
 
 
 
83.0 per million inhabitants per year, from 
this one-third of the patients are reported to 
have tetraplegia and 50% have complete 
lesions at the mean age of 33.  
In the Department of Neurosurgery of 
the Cluj County Emergency the incidence 
of SCI operated cases have increased from 
45 cases/year in 2000 to 159 in 2009 due to 
the dramatically growth of the number of 
traffic accidents, thus increasing the 
addressability of our department  in respect 
to the nationwide programme for 
preventing spinal deformity after spine 
injury. 
Contrary to his important impact, the 
therapeutic armamentarium is very limited 
and there is no effective treatment to 
diminish the damage or to promote 
functional recovery.  
If the rationale of early surgery is 
decompression, in order to theoretically 
limit the secondary injury by diminishing 
the local ischemia, and stabilization in order 
to prevent subsequent lesion by an unstable 
spine, for secondary injury there are no 
available clinical proven therapies, in spite 
of numerous tested drugs in vitro and in 
vivo conditions. 
In theory it is possible that at the time of 
the surgery to add some factors that could 
block the secondary injury’s cascade or 
could promote neuronal or axonal recovery 
at the site of lesion. 
The great problem is to find the proper 
factors and the proper way of releasing at 
the site of the injury. For that reason we 
designed an experimental study in order to 
find some substances and the proper way of 
administration to improve the neurological 
evolution of this disabling disease. 
Material and method 
Twenty-four albino Wistar rats (weight 
approximately 180-250g) were used during 
the study. The rats were anesthetized with 
Ketamine 75-100 mg/kg, Xylazine 10mg/kg, 
intraperitoneally. A longitudinal incision 
was made on the midline of the back, and 
the paravertebral muscles were dissected to 
expose vertebrae T8 to T10. A three level 
(T8-T10) laminectomy was performed to 
expose the spinal cord with the intact dura 
matter. In the absence of a standard 
impactor, the spinal cord injury was 
produced by applying a Yasargil temporary 
clip 50 grams pressure force for 1 minute, 
the produced lesions mimicking 
compression- luxation injury. The layers 
were closed with 3/0 silk. 
Study groups  
Immediately after SCI the rats were 
randomly grouped in 4 study groups of 6 
rats each either : Group MP – single dose 
intrathecal administration of 30mg/kg 
metilprednisolon 10 minutes after spinal 
cord injury; Group C- daily intraperitoneal 
administration of 2,5ml/kg of Cerebrolysine 
for 10 days; Group MP+C - single dose 
intratecal administration of 30mg/kg at 10 
minutes after spinal cord injury and 
2,5ml/kg daily, for ten days, i.p.; Control 
Group  – decompression only ( T8-T10 
laminectomy has a decompressive role in 
condition of spinal cord injury).  Ten days 
after the injury the rats were anesthetized 
(60 mg/kg intraperitoneally) and then 
decapitated. The spinal cords were rapidly 
removed and preserved in 10% neutral 
formaldehyde solution. 
Histopathologic examination 
Serial sections were taken from 2 mm 
caudal and rostral to and from the 
epicenter, tissue sections being stained with 
hematoxylin-eosin before light microscope 
examination. 
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Figure 1 There are no clear differences between the four groups concerning the pathological aspects in H –E 
staining below 40 x magnifications. In all cases it can be observed a large vacuolization, disorganization of white 
mater; the nuclei are hipercromatic with nucleollyses. At the level of a dorsal root there are large 
demielinisations 
 
Neurological evaluation  
For the motor evaluation of the Wistar 
rats we used the BBB Locomotor         
Rating Scale modified by Ferguson et al. 
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TABLE 1 
Ferguson et al. Modification of the BBB 
Locomotor Rating Scale 
0 No observable hind limb (HL) movement 
1 Slight movement of one or two joints, usually 
the hip and/or knee 
2 Extensive movement of one or two joints  
or 
Extensive movement of one joint and slight 
movement of one other joint 
or 
Slight movement of all three joints 
3 Slight movement of two joints and extensive 
movement of the third 
4 Extensive movement of two joints and slight 
movement of the third 
5 Extensive movement of all three joints of the 
HL 
6 Sweeping with no weight support 
or  
Plantar placement of the paw with no weight 
support 
7 Plantar placement of the paw with weight 
support in stance only (i.e., when stationary) 
or 
Occasional, frequent, or consistent weight 
supported dorsal stepping and no plantar 
stepping 
8 Occasional weight supported plantar steps, no 
forelimb (FL)-HL coordination 
9 Frequent to consistent weight supported 
plantar steps and no FL-HL coordination 
10 Frequent to consistent weight supported 
plantar steps and occasional FL-HL 
coordination 
11 Frequent to consistent weight supported 
plantar steps and frequent FL-HL 
coordination 
12 Consistent weight supported plantar steps, 
consistent FL-HL coordination 
or 
Frequent plantar stepping, consistent FL-HL 
coordination, and occasional dorsal stepping 
 
Definitions: 
Slight: partial joint movement through 
less than half the range of joint motion. 
Extensive: movement through more 
than half of the range of joint motion. 
Sweeping: rhythmic movement of HL 
in which all three joints are extended, then 
fully flex and extend again; animal is usually 
side lying, the plantar surface of paw may or 
may not contact the ground; no weight 
support across the HL is evident.  
No weight support: no contraction of 
the extensor muscles of the HL during 
plantar placement of the paw; or no 
elevation of the hindquarter. 
Weight support: contraction of the 
extensor muscles of the HL during plantar 
placement of the paw; or elevation of the 
hindquarter. 
Plantar stepping: the paw is in plantar 
contact with weight support then the HL is 
advanced forward and plantar contact with 
weight support is reestablished. 
Dorsal stepping: weight is supported 
thorough the dorsal surface of the paw at 
some point in the step cycle. 
FL-HL coordination: for every FL 
step an HL step is taken and the HLs 
alternate. 
Occasional: less than or equal to half; 
Frequent: more than half but not 
always: 51–94% 
Consistent: nearly always or always; 
95–100% 
 
The data were statistically analyzed with 
T test and One Way ANOVA methods. For 
the quantitative variables this analysis was 
done by observing the minimum and 
maximum values and calculating their 
means, standard deviations and medians. 
Absolute and percentage frequencies were 
also calculated. 
Results 
There were no statistically significant 
differences between control group and the 
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one who received Methylprednisolone 
(MP) regarding motor recovery. (p=0,89) 
(Figure 2). 
The same lack of significance was 
observed between control group and the 
group that received Cerebrolysin (C) (p= 
0,79) (Figure 3). 
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 Figure 2 Motor recovery in the control group 
compared to the group that received 
Methylpredinisolone (MP) 
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 Figure 3 Motor recovery in the control group 
compared to the group that received  
Cerebrolysin (C) 
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 Figure 4 Motor recovery in the control group 
compared to the group that received 
Methylprednisolone and Cerebrolysin 
 
Average values of  scores obtained by rats 
in the control group are not significantly 
higher than that the values obtained by the  
rats which received the combination of 
Methylprednisolone (MP) and 
Cerebrolysin (C) (Figure 4). 
One way ANOVA methods showed no 
statistically significant differences between 
different  groups in terms of motor 
recovery in rats. (Figure 4). The MP and C 
group presented functional results that 
were better than those of the control group 
but no statistically significant (p> 0,05). 
Discussion  
Several experimental models have been 
described for producing a spinal cord 
injury. Experimental evaluations of the 
effectiveness of a drug for animals with a 
spinal cord injury require the production of 
a standardized injury that has a motor 
function response as similar as possible 
among many animals. We choose to use the 
clip-compression model because it allows a 
precise monitoring of the force (50g) and 
duration of compression (1 minute). It is 
also a more subtle technique.  
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ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Bonferroni's Multiple Comparison Test
Control group vs Methylprednisolone group
Control group vs Cerebrolysin group 
Control group vs MP+ C group
Methylprednisolone group vs Cerebrolysin group 
Methylprednisolone group vs MP+ C group
Cerebrolysin group  vs MP+ C group
0.3263
0.9550
ns
No
SS
12.60
1921
1934
Mean Diff.
-0.4000
-0.9000
-1.500
-0.5000
-1.100
-0.6000
df
3
36
39
t
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0.4591
0.1530
0.3367
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MS
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No
No
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ns
ns
ns
ns
ns
ns
95% CI of diff
-9.522 to 8.722
-10.02 to 8.222
-10.62 to 7.622
-9.622 to 8.622
-10.22 to 8.022
-9.722 to 8.522
Figure 5 Comparative analysis of the results obtained from the four groups 
 
The ideal tool for evaluation of motor 
function should be sensitive, easy to use, 
and able of showing small changes. Today, 
the evaluation method that comes closest to 
those purposes is the BBB Scale.  Because 
the discontinuous nature of the lower 
portion of the scale presents a problem for 
both parametric and nonparametric 
statistical [1] we used a modification of the 
scale after Ferguson et al. 
In our study we sacrificed animals ten 
days after the spinal cord trauma as the 
purpose was to analyze the functional 
recovery during the acute phase. We choose 
to use Methylprednisolone because it 
provides clinical benefits and also 
improvement in neurological function as 
demonstrated in several studies [4,12]. 
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Cerebrolysin contains a mixture of 
neurotrophic peptide and it was proven to 
be a useful treatment for enhancing 
neurological recovery after stroke [13].  
The rationale for our experimental study 
was to add neuroprotective factors with 
multiple mechanisms of action on both 
local and general modes in order to 
augment the neuroprotective effect 
Methylprednisolone is a glucocorticoid 
with potent anti-inflammatory properties. 
This group of drugs induced synthesis and 
release of many anti-inflammatory peptides. 
Among them, lipocortins inhibit calcium 
activated phospholipase activity by binding 
to membrane phospholipid substrates. 
Methylprednisolone is not only an anti-
inflammatory drug but also a potent 
immunosuppressive. This drug inhibits 
phospholipase A2 activity, alters neuronal 
excitability and improves post-traumatic 
spinal cord blood flow. 
Yoon et all showed that 
Methylprednisolone has a very short 
therapeutic window and the best results are 
obtained with a dose of 30 mg/kg applied 
within the first 30 minutes after contusion 
[7]. Based on that study, we administrated 
30 mg/kg Methylprednisolone 10 minutes 
after the injury.  
High dose of Methylprednisolone causes 
adverse side effects including pneumonia, 
wound infections and acute corticosteroid 
myopathy accompanied by only modest 
improvements in neurological recovery [8, 
17]. There is a need for localized delivery of 
MP to the lesion site to minimize the 
systemic delivery related side effects. To 
achieve this local delivery, we injected the 
drug into the spinal cord, at the site of 
injury. 
The glucocorticoid steroids were widely 
used in the clinical treatment of spinal cord 
trauma by the middle of the 60’s and 
throughout the 1970. The rationale 
mechanism for their use was centered on 
the expectation that they would reduce the 
spinal cord edema. This was based upon the 
remarkable reduction of peritumoral brain 
edema 
The first National Acute Spinal Cord 
Study (NASCIS 1) that began in 1979 
wanted to compare high and low dose of 
Methylprednisolone in spinal cord injury. 
The trial did not involve a placebo group. 
The study was published in 1985 and found 
no significant difference between high and 
low dose of Methylprednisolone started 
within 48 hours after spinal cord injury. 
There also was a suggestion that the 10-
days high-dose regimen increased the risk 
of infections. The study raised question at 
that time about the efficiency of 
glucocorticoids and brought to the 
forefront the teory of free radicals. 
In 1990 the second National Spinal 
Cord Injury Study (NASCIS 2) showed a 
significant improvement in motor and 
sensory recover in patients treated with 
high dose of Methylprednisolone within 8 
hours after spinal cord injury. However, 
when started more than 8 hours after the 
injury the drug was proven not only 
ineffective but deleterious. This study 
suggests that a therapeutic time window 
exists in spinal cord injury. 
Weaver et all demonstrated that the non-
selective and enduring effects of 
immunosuppressive therapy with 
Methylprednisolone not only fail to 
improve neurological outcomes in rats with 
spinal cord injury, but also can block the 
beneficial actions of selective therapies 
(anti-CD11d mAb) [25]. 
Cerebrolysin is a neurotrophic 
peptidergic mixture with antioxidant 
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properties. The drug has been studied since 
the early 1970’s. In stroke and 
neurodegenerative diseases, double-blind 
placebo controlled trials have reported 
sustained improvements and slowing down 
of progressive memory loss, cognition 
impairment, mood changes, and motor and 
sensory symptoms 
Several studies have suggested that 
Cerebrolysin has neurotrophic and 
neuroprotective effect in vitro and in vivo. 
In animals, following cerebral ischemia, 
Cerebrolysin has been shown to ameliorate 
the effect of oxidative cell stress [9]. The 
inhibitory effect of the drug on calpain has 
been demonstrated on a molecular level 
[26]. Cerebrolysin reduces apoptosis 
triggered by growth factor withdraw and 
induces neuritis outgrowth in cultivated 
neurons [20].   
Tatebayashi et all demonstrated that 
Cerebrolysin enhanced neurogenesis in the 
dentate gyrus of adult animals, which 
correlates with improved spatial memory 
performance in these animals [24]. After 
bilateral artery occlusion in rats, 
Cerebrolysin reduces mortality of the 
animals with about 50 %, and also reduces 
the infarct size as well as the loss of MAP-2 
immunoreactivity in a middle cerebral 
artery occlusion model [22, 23]. In humans 
the drug was safely used for the treatment 
of several conditions [3, 16, 18]. 
Haninec, et al. reported that insulin-like 
growth factor I (IGF-I) and Cerebrolysin 
enhances survival of motoneurons after 
ventral root avulsion [18]. The drugs were 
effective when given intrathecally to the 
spinal cord. In 2005, Bul’on, et al published 
a study that compared the effects of 
cytoflavin and Cerebrolysin in rats after 
spinal cord compression injury [5]. The 
neuroprotective effects of cytoflavin were 
greater than of   Cerebrolysin’s. 
In 1999, Lombardi, et al [14] 
demonstrated that applying Cerebrolysin to 
astrocytes and microglia cultures of rats, 
prevented microglial activation after LPS 
activation and reduced interleukin-1b 
expression. Mallory, et al. [15] reported 
that when the peptide mixture was applied 
to the human teratocarcinoma cell line 
(NT2) Cerebrolysin markedly increased 
expression of synaptic-associated proteins, 
suggesting that it has synaptotrophic effects 
mediated through regulation of APP 
expression. Alvarez, et al. showed that this 
drug reduced microglial activation both in 
vitro and in vivo [2]. 
 In 2002 Guttmann et al.  demonstrated 
that Cerebrolysin protects cortical neurons 
cultures of the chickens from cell death 
caused by a wide variety of factors, 
including glutamate, iodoacetate, and 
ionomycin; they proposed that 
Cerebrolysin stabilizes calcium ionic 
homeostasis [10]. Safarova, et al. [19] 
showed that Cerebrolysin improved 
survival of PC12 cells in serum-free 
medium. They obtained a decrease of 
apoptosis from 32% to 10%. In 2005, 
Schauer, et al. found that a single addition 
of Cerebrolysin to culture medium resulted 
in significant protection of tissue cultures 
against ischemia and hypoxia for up to 2 
weeks. The treatment has the same 
beneficial effects even if it is delayed for as 
long as 96 hours [21].  
Our study has some weakness that could 
affect the results. Firstly the traumatic 
model is not largely accepted, the produced 
lesions being possibly too severe, and as a 
consequence, irreversible. Secondly the 
local administration of Methyprednisolone 
could be harmful per se, adding possible 
new lesions, in the absence of a special 
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device for microinjection. More than that it 
is uncertain if the injectable form we used is 
compatible with a local administration. On 
the other hand it is known that 
Cerebrolysin is a dose dependent drug. 
In spite of these criticisms, from our 
knowledge this is the first experimental 
study of a combination between MP and 
Cerebrolysin in SCI. Their mechanism of 
action is not completely understood, but 
there are experimental data demonstrating 
an apoptotic inhibition on the line of 
calpains. At least for MP there are 
experimental data proving the favourable 
action on topic application [6] 
More experimental data are necessary in 
order to demonstrate the synergic action of 
MP and Cerebrolysin, the optimal interval 
for drug administration and the optimal 
dose of the drugs taking into account that at 
a dose of 30mg/kg MP have many 
deleterious effects. Cerebrolysin is a dose 
dependent drug and until now there are no 
studies regarding the local application of 
this drug. 
Finally, taking in consideration that in 
control group, the simple laminectomy 
group, the results were no significantly 
different that in those medically treated, the 
role of urgent decompressive laminectomy 
cannot be underestimated. 
Conclusion 
We found that Methylprednisolone and 
Cerebrolysin didn’t significantly enhanced 
neurological recovery in rats with severe 
clip-compression models of spinal cord 
injury, administrated alone or in 
combination from a statistic point of view.  
Methylprednisolone is the first drug 
shown to improve recovery in human 
spinal cord injury and remains the only 
form of treatment shown in a phase 3 trial 
to have efficiency in managing this injury. 
Therefore, it remains the standard therapy 
to which all further treatments should be 
compared.   
Some clinical evidence suggest that 
Cerebrolysin may be beneficial for many 
neurological conditions, including 
extrapyramidal hyperkinesis associated to 
narcoleptic therapy, acute and chronic 
stroke, brain trauma, organic mental 
disorders, ischemic encephalopathy, 
diabetic neuropathy, Rett syndrome, 
vascular dementia, multiple sclerosis, anti-
aging and other neurodegenerative 
disorders. Little data is available concerning 
the effect of Cerebrolysin on spinal cord 
injury. More studies are needed to ascertain 
the benefits of the drug for both acute and 
chronic spinal cord injuries. 
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